Eventide Asset Management - Q1 2014 holdings

$644 Million is the total value of Eventide Asset Management's 101 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 16.0% .

 Value Shares↓ Weighting
AGIO BuyAGIOS PHARMACEUTICALS INC$17,782,000
+255.6%
454,200
+117.5%
2.76%
+79.1%
MDVN BuyMEDIVATION INC$17,026,000
+97.9%
264,500
+96.2%
2.64%
-0.3%
CBI BuyCHICAGO BRIDGE & IRON CO N V$16,890,000
+96.5%
193,800
+87.4%
2.62%
-1.0%
TRW BuyTRW AUTOMOTIVE HLDGS CORP$16,193,000
+103.3%
198,400
+85.2%
2.51%
+2.4%
ABBV BuyABBVIE INC$14,793,000
+88.6%
287,800
+93.8%
2.30%
-5.0%
MIC BuyMACQUARIE INFRASTR CO LLCmembership int$14,615,000
+92.2%
255,200
+82.7%
2.27%
-3.2%
UFS BuyDOMTAR CORP$14,510,000
+99.2%
129,300
+67.5%
2.25%
+0.4%
MGA BuyMAGNA INTL INC$14,418,000
+116.4%
149,700
+84.4%
2.24%
+9.0%
EOG BuyEOG RES INC$14,203,000
+123.9%
72,400
+91.5%
2.20%
+12.8%
PANW BuyPALO ALTO NETWORKS INC$14,104,000
+116.0%
205,600
+81.0%
2.19%
+8.9%
SUNEQ BuySUNEDISON INC$13,736,000
+182.3%
729,100
+95.5%
2.13%
+42.2%
WBC BuyWABCO HLDGS INC$13,554,000
+104.4%
128,400
+80.8%
2.10%
+3.0%
LEA BuyLEAR CORP$13,471,000
+91.7%
160,900
+85.4%
2.09%
-3.4%
TEX NewTEREX CORP NEW$13,445,000303,500
+100.0%
2.09%
LLTC BuyLINEAR TECHNOLOGY CORP$13,302,000
+103.5%
273,200
+90.4%
2.06%
+2.5%
MEOH BuyMETHANEX CORP$12,871,000
+79.6%
201,300
+66.4%
2.00%
-9.5%
ROC NewROCKWOOD HLDGS INC$12,678,000170,400
+100.0%
1.97%
ININ BuyINTERACTIVE INTELLIGENCE GRO$12,390,000
+1126.7%
170,900
+1039.3%
1.92%
+518.3%
RHT BuyRED HAT INC$12,307,000
+73.9%
232,300
+83.9%
1.91%
-12.4%
LOW BuyLOWES COS INC$11,853,000
+81.5%
242,400
+83.9%
1.84%
-8.5%
DYAX BuyDYAX CORP$11,476,000
+47.1%
1,278,000
+23.3%
1.78%
-25.9%
PCYC BuyPHARMACYCLICS INC$11,165,000
+58.5%
111,400
+67.3%
1.73%
-20.1%
WAB BuyWABTEC CORP$10,517,000
+95.0%
135,700
+86.9%
1.63%
-1.7%
LYB BuyLYONDELLBASELL INDUSTRIES N$10,130,000
+53.3%
113,900
+38.4%
1.57%
-22.7%
FPRX NewFIVE PRIME THERAPEUTICS INC$10,090,000513,200
+100.0%
1.57%
LGND BuyLIGAND PHARMACEUTICALS INC$9,948,000
+40.7%
147,900
+10.0%
1.54%
-29.1%
STKL BuySUNOPTA INC$9,715,000
+81.8%
822,600
+54.0%
1.51%
-8.4%
IPHI BuyINPHI CORP$9,707,000
+120.0%
603,300
+76.4%
1.51%
+10.8%
CCI BuyCROWN CASTLE INTL CORP$9,643,000
+193.1%
130,700
+191.7%
1.50%
+47.6%
PTLA BuyPORTOLA PHARMACEUTICALS INC$9,415,000
+111.0%
363,500
+109.8%
1.46%
+6.3%
CMRX NewCHIMERIX INC$9,408,000411,900
+100.0%
1.46%
CXP NewCOLUMBIA PPTY TR INC$9,151,000335,800
+100.0%
1.42%
CPN BuyCALPINE CORP$8,868,000
+52.8%
424,100
+42.6%
1.38%
-23.0%
ASML BuyASML HOLDING N V$8,757,000
+79.7%
93,800
+80.4%
1.36%
-9.5%
P103PS BuyNPS PHARMACEUTICALS INC$8,497,000
+15.3%
283,900
+17.0%
1.32%
-41.9%
VMW NewVMWARE INC$8,490,00078,600
+100.0%
1.32%
SGMO BuySANGAMO BIOSCIENCES INC$8,362,000
+177.1%
462,500
+112.8%
1.30%
+39.6%
NVAX BuyNOVAVAX INC$7,886,000
+19.6%
1,740,900
+35.2%
1.22%
-39.7%
CMRE BuyCOSTAMARE INC$7,744,000
+142.6%
360,200
+106.2%
1.20%
+22.3%
AYR BuyAIRCASTLE LTD$7,744,000
+25.3%
399,600
+23.9%
1.20%
-36.9%
SDRL BuySEADRILL LIMITED$7,718,000
+31.1%
219,500
+53.2%
1.20%
-34.0%
OII BuyOCEANEERING INTL INC$7,466,000
+15.7%
103,900
+27.0%
1.16%
-41.7%
STML BuySTEMLINE THERAPEUTICS INC$7,378,000
+80.9%
362,400
+74.1%
1.14%
-8.9%
SCTY  SOLARCITY CORP$7,139,000
+10.2%
114,0000.0%1.11%
-44.5%
BWA  BORGWARNER INC$6,922,000
+10.0%
112,6000.0%1.08%
-44.6%
KAR  KAR AUCTION SVCS INC$6,452,000
+2.7%
212,6000.0%1.00%
-48.2%
FC BuyFRANKLIN COVEY CO$6,239,000
+15.5%
315,600
+16.1%
0.97%
-41.8%
SRPT BuySAREPTA THERAPEUTICS INC$6,226,000
+115.6%
259,100
+82.7%
0.97%
+8.7%
NRG  NRG ENERGY INC$6,150,000
+10.7%
193,4000.0%0.96%
-44.2%
NLNK BuyNEWLINK GENETICS CORP$6,126,000
+76.9%
215,700
+37.1%
0.95%
-10.9%
TSLA BuyTESLA MTRS INC$5,482,000
+155.0%
26,300
+83.9%
0.85%
+28.5%
AZPN NewASPEN TECHNOLOGY INC$5,443,000128,500
+100.0%
0.84%
CLDX BuyCELLDEX THERAPEUTICS INC NEW$5,101,000
-18.0%
288,700
+12.3%
0.79%
-58.7%
PWR BuyQUANTA SVCS INC$4,945,000
+98.1%
134,000
+69.4%
0.77%
-0.1%
ACAD BuyACADIA PHARMACEUTICALS INC$4,708,000
+7.4%
193,500
+10.3%
0.73%
-45.9%
PBYI BuyPUMA BIOTECHNOLOGY INC$4,676,000
+7.3%
44,900
+6.7%
0.73%
-45.9%
SJM BuySMUCKER J M CO$4,512,000
+20.6%
46,400
+28.5%
0.70%
-39.2%
SZYM BuySOLAZYME INC$4,226,000
+60.9%
364,000
+50.9%
0.66%
-18.9%
NOV  NATIONAL OILWELL VARCO INC$3,699,000
-2.1%
47,5000.0%0.57%
-50.7%
TTPH BuyTETRAPHASE PHARMACEUTICALS I$3,277,000
+150.9%
300,900
+211.5%
0.51%
+26.6%
ATRC BuyATRICURE INC$2,705,000
+108.9%
143,800
+107.5%
0.42%
+5.3%
ECYT BuyENDOCYTE INC$2,333,000
+377.1%
98,000
+114.4%
0.36%
+139.7%
PRTA NewPROTHENA CORP PLC$2,233,00058,300
+100.0%
0.35%
SLXP BuySALIX PHARMACEUTICALS INC$2,124,000
+162.5%
20,500
+127.8%
0.33%
+32.5%
KPTI BuyKARYOPHARM THERAPEUTICS INC$2,094,000
+208.8%
67,800
+129.1%
0.32%
+55.5%
CERN NewCERNER CORP$2,070,00036,800
+100.0%
0.32%
CBST BuyCUBIST PHARMACEUTICALS INC$2,004,000
+144.4%
27,400
+130.3%
0.31%
+22.9%
CLVS NewCLOVIS ONCOLOGY INC$1,960,00028,300
+100.0%
0.30%
SUPN NewSUPERNUS PHARMACEUTICALS INC$1,927,000215,500
+100.0%
0.30%
BMRN BuyBIOMARIN PHARMACEUTICAL INC$1,917,000
+162.2%
28,100
+170.2%
0.30%
+32.4%
SAAS  INCONTACT INC$1,856,000
+22.9%
193,3000.0%0.29%
-38.1%
HPTX BuyHYPERION THERAPEUTICS INC$1,850,000
+193.2%
71,700
+129.8%
0.29%
+47.9%
NTUS BuyNATUS MEDICAL INC DEL$1,834,000
+164.6%
71,100
+130.8%
0.28%
+33.8%
OMED BuyONCOMED PHARMACEUTICALS INC$1,777,000
+167.6%
52,800
+134.7%
0.28%
+34.6%
BRKR BuyBRUKER CORP$1,684,000
+178.3%
73,900
+141.5%
0.26%
+40.3%
ACRX BuyACELRX PHARMACEUTICALS INC$1,674,000
+179.5%
139,400
+163.0%
0.26%
+40.5%
CSII BuyCARDIOVASCULAR SYS INC DEL$1,675,000
+114.2%
52,700
+131.1%
0.26%
+7.9%
CEMP BuyCEMPRA INC$1,654,000
+107.5%
143,200
+122.7%
0.26%
+4.5%
FMI BuyFOUNDATION MEDICINE INC$1,593,000
+481.4%
49,200
+327.8%
0.25%
+194.0%
MGNX BuyMACROGENICS INC$1,564,000
+200.2%
56,200
+195.8%
0.24%
+50.9%
FEIC BuyFEI CO$1,525,000
+184.5%
14,800
+146.7%
0.24%
+43.6%
MEIP BuyMEI PHARMA INC$1,515,000
+204.8%
136,100
+119.2%
0.24%
+53.6%
BLUE BuyBLUEBIRD BIO INC$1,478,000
+174.2%
65,000
+152.9%
0.23%
+38.0%
SHPG BuySHIRE PLCsponsored adr$1,456,000
+61.1%
9,800
+53.1%
0.23%
-18.7%
ATHN BuyATHENAHEALTH INC$1,426,000
+165.1%
8,900
+122.5%
0.22%
+33.1%
NBIX BuyNEUROCRINE BIOSCIENCES INC$1,406,000
+290.6%
87,300
+126.8%
0.22%
+96.4%
INSM BuyINSMED INC$1,371,000
+144.8%
72,000
+118.8%
0.21%
+23.1%
XOMA BuyXOMA CORP DEL$1,340,000
+63.8%
257,200
+111.5%
0.21%
-17.5%
AMBI BuyAMBIT BIOSCIENCES CORP$1,196,000
+67.5%
131,100
+76.9%
0.19%
-15.5%
COG  CABOT OIL & GAS CORP$1,193,000
-12.5%
35,2000.0%0.18%
-56.0%
MDSO BuyMEDIDATA SOLUTIONS INC$1,027,000
+21.1%
18,900
+35.0%
0.16%
-39.1%
PCRX  PACIRA PHARMACEUTICALS INC$931,000
+21.7%
13,3000.0%0.14%
-38.6%
ATHX BuyATHERSYS INC$860,000
+94.1%
265,300
+49.8%
0.13%
-1.5%
RGEN  REPLIGEN CORP$691,000
-5.6%
53,7000.0%0.11%
-52.7%
MDAS  MEDASSETS INC$655,000
+24.8%
26,5000.0%0.10%
-37.0%
TFX  TELEFLEX INC$622,000
+14.3%
5,8000.0%0.10%
-42.3%
SNSS  SUNESIS PHARMACEUTICALS INC$607,000
+39.5%
91,8000.0%0.09%
-29.9%
CERS  CERUS CORP$469,000
-25.7%
97,8000.0%0.07%
-62.4%
RMD  RESMED INC$442,000
-5.2%
9,9000.0%0.07%
-52.1%
RPTP  RAPTOR PHARMACEUTICAL CORP$404,000
-23.2%
40,4000.0%0.06%
-61.1%
HTWR  HEARTWARE INTL INC$291,0000.0%3,1000.0%0.04%
-50.0%
VVUS ExitVIVUS INC$0-27,900
-100.0%
-0.08%
ONTX ExitONCONOVA THERAPEUTICS INC$0-23,000
-100.0%
-0.08%
DWSN ExitDAWSON GEOPHYSICAL CO$0-65,300
-100.0%
-0.68%
ExitASPEN TECHNOLOGY INC$0-128,500
-100.0%
-1.66%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2014-05-13
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q1 2014 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings